Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD
Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $64.11, marking a -0.9% move from the previous day.
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.
Why Viking Therapeutics Stock Topped the Market Today
An analyst waxed bullish on the company's leading pipeline program.
Is Viking Therapeutics Stock a Buy?
Investors have piled into the biotech because of its weight-loss drug candidate. There are already some hugely successful products on pharmacy shelves.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.
Is Viking Therapeutics Ready For Another Surge?
Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $63.13, representing a +1.94% change from its previous close.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
An analyst reiterated his optimistic stance on the biotech. Like many others, he feels its leading investigational drug has great potential.
Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks
Viking Therapeutics' weight-loss drug VK2735 shows strong efficacy, likely leading to an acquisition by a large pharmaceutical firm, in my opinion. But the firm faces significant risks and competition. The timeline for a takeover bid may be longer than expected, and the acquisition price could be lower than bullish estimates. Marketing VK2735 independently or finding a strategic partner will be challenging, yet the stock is a buy for patient, risk-tolerant, long-term investors.
